ReviewCurrent hematologic malignancy reports2024
Update on T-Cell Lymphoma Epidemiology.
Review in Current hematologic malignancy reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Real-World Outcomes of Belinostat in Relapsed Refractory T-Cell Lymphomas: A Report from the Lymphoma Study Group of Turkish Society of Hematology.Journal of clinical medicine · 2026Article
- Review
- Prediction of early death in peripheral T-cell lymphoma-NOS patients based on machine learning.Annals of hematology · 2026Article
- Oral manifestations of anaplastic large cell lymphoma: clinicopathological features and main immunophenotypic findings of 3 cases.Journal of hematopathology · 2026Article
- Patterns of care and clinical outcomes in systemic peripheral T-cell lymphoma: the LEO-MER prospective cohort study.Blood advances · 2026Observational
- Prognostic significance of quantitative EBV biomarkers in extranodal NK/T-cell lymphoma: a meta-analysis of EBV DNA load and EBER-positive cell proportion.Infectious agents and cancer · 2026Review
- A rare collision tumor of lymphoepithelioma-like carcinoma and t-cell lymphoma: a case report.Frontiers in oncology · 2026Article
- Survival analysis and prognostic factors of mature T-cell and natural killer/T-cell neoplasms in Colombian patients from 2008-2025.Frontiers in oncology · 2026Article
- Retrospective analysis of clinical characteristics, treatment outcomes and prognosis of patients with natural killer/T-cell lymphoma.Oncology letters · 2026Article
- Identification of Trogocytosis as an Essential Limitation Factor in hPSC-derived CAR Macrophages.International journal of biological sciences · 2026Article
- Rare case report and literature review of peripheral T-cell lymphoma presenting as massive gastrointestinal hemorrhage: an unusual etiology demanding emergency surgical intervention.Frontiers in oncology · 2026Article
- [Chinese expert consensus on the diagnosis and management of nodal peripheral T-cell lymphoma (2025)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Population Pharmacokinetics of Valemetostat and Exposure-Response Analyses of Efficacy and Safety in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma.Journal of clinical pharmacology · 2025Article
- Epidemiology of mature T-cell and NK-cell neoplasms: east and west.The Lancet regional health. Western Pacific · 2025Review
- Nodal peripheral T-cell lymphoma in Finland between 2007 and 2019: Incidence, late morbidity and survival.British journal of haematology · 2025Article
- Peripheral T-Cell Lymphoma, Not Otherwise Specified, Diagnosed from Prostate Tissue: A Rare CaseTurkish journal of haematology : official journal of Turkish Society of Haematology · 2025Article
- Sex-specific differences in reproductive tract lymphomas: epidemiology, clinical features, and treatment outcomes.The oncologist · 2025Article
- Review
- EntitiesHaematologica · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewT-cell lymphomas (TCLs) are a group of rare subtypes of non-Hodgkin lymphoma derived from mature T-lymphocytes. Recent updates in lymphoma classification based on the cell-of-origin pathogenesis have shed new light on TCL epidemiology and outcomes. Contemporary regional consortia and international studies, including those conducted recently in Asia and South America, have provided an updated delineation of the major subtypes across various global regions. RECENT
findingsPeripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), remains the most common subtype globally except in Asia, where extra-nodal NK-T cell lymphoma (ENKTL) has emerged as the most prevalent. Angioimmunoblastic T-cell lymphoma (AITL) is the second most common subtype globally except in South America where its incidence falls behind adult T-cell leukemia/lymphoma (ATLL) and ENKTL. ALK-negative anaplastic large cell lymphoma (ALCL) has been recognized as the second most common subtype in some parts of South America. Studies on the newly classified breast implant-associated ALCL (BIA-ALCL) are beginning to reveal its distribution and risk factors. Deciphering the epidemiology of TCLs is a challenging endeavor due to the rarity of these entities and ongoing refinement in classification. Collaborative efforts on prospective registries based on the most current WHO classifications will help capture the true epidemiology of TCL subtypes to better focus resources for diagnostic, prognostic, and therapeutic efforts.
Indexed as
Identifiers
38451372What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.